Assisted Reproduction

IVF, IUI & ICSI

The global average success rate in Assisted Reproduction Techniques (ART) such as IVF, IUI & ICSI among others is about 24% and the highest in the world is seen in Japan at 35%. India is estimated to have a success rate in fertility care outcome of ~18%.

Innerorgans

ONE out of every FIVE couple globally are infertile

A 30-year-old working female has a reproductive age of over 42 years resulting in significantly reduced chance of having a child naturally. Inner organs are aging rapidly due to life-style, environmental & occupational disorders in the life of most working professional. Reports indicate ONE out of every FIVE couple globally are infertile.

Inadequate Lifestyle

Lifestyle habits and inadequate sleep has caused the regenerative capability of the reproductive system to be significantly compromised leading to over 1 in 5 couple in the reproductive age having difficulty in conceiving naturally.

Health IT systems

Inadequate use of Health IT systems such as CIS, LIS, EMR etc. has led majority of the decision being influenced by the biases of the practitioner as against adopting Evidence Based Medicine practice in the specialty which produces a dismal
< 20% successful pregnancy.

Physiological Complications

With the physiological complications increasing in the reproductive system, the need for adaptive hardware-software simulation system has been identified to help save a large number of patients whose clinical outcomes are not good owing to the learning happening on the patient rather than using a simulator.

About Innov4Sight

Goal – Scope for Scalability

We now believe that we're adequately equipped (technically) to create one of the largest chain of technology driven Fertility Clinics across the globe within 4 years.

We aspire to have 300 Vyabl Clinics in India & 150 Clinics outside India within 4 years.

We estimate that to setup 450 Clinics (ranging from small OP based fertility clinics to full service woman care nursing home) the budget can be well over $ 200 million but using our technology stack we can roll-out and commercially make it viable at a budget that is only 1/8th of the brick & mortar setup but will still generate in excess of 50% revenue compared to a brick & mortar.

CONTACT DETAILS

Call +91-8026722707

Market Size / Opportunity

India has over 3 Crore infertile couple in the reproductive age group. Japan is already facing negative population growth. Over 20 countries globally are rapidly moving towards negative population growth. About 18 countries globally are spending billions of dollars in addressing infertility as a public health issue ranging from Singapore, Japan, Israel, UK to more recently India.

BBC quoted “China has decided to end its decades-long one-child policy, the state-run Xinhua news agency reports. Couples will now be allowed to have two children, it said, citing a statement from the Communist Party.”

Government of Madhya Pradesh in May 2016 launched a 100 Crore scheme (co-funded by National Health Mission) to offer free fertility care at District Health Centres across the State. The scheme name ‘ROSHNI’ is intended to give hope & more certainty to lakhs of people affected the State due to infertility challenges. Following this other States such as Goa & Tamil Nadu have also initiative schemes to address infertility as a Public Health initiative.

Impact

While our venture is primary driven by profitability considering that about 70% of infertile couple in India cannot afford the expensive treatment our technology stack can enable PPP initiative PAN India reducing the cost of fertility care by over 60%.

General perception is that India is overpopulated but the reality is that it’s a myth with India reaching replacement levels of fertility by 2020. Similar to India many would presume that China is also overpopulated but the two-child policy rolled out by China indicates that perception is not a reality.

Traction

Regen Med

A Clinical Study of over 130 patients have been concluded with a >70% successful pregnancy rate. The male related clinical study is still in progress. To date, we’ve served BAP.C to over 520 women and continue to provide a significant success in the Clinical Outcome during ART procedures.

Medical Simulators

Fertilator was launched at Singapore General Hospital’s Starting Out on Assisted Reproduction 2018 (SGH’s SOAR) in May 2018 with over 36 Doctors from 6 Countries evaluating our simulator and providing rave reviews. We’re looking at making the device commercially available by end of the year.

B2C initiative

Complementing the B2C initiative i.e. Vyabl is a B2B toolset including a Fertility EMR & CDSS that is being piloted across multiple partner clinics.

Technology – Products & Solutions

Our solution to addressing the rapid reproductive aging problem is a Regenerative Medicine Solution for Male & Female Infertility that improves the physiological conditions and functions of the reproductive system for better Clinical Outcomes during ART procedures.

Vyabl is a digital health platform that is intended to serve as an ecosystem for fertility care from spreading awareness using questionnaire through diagnostics screening to facilitation of actual fertility procedures through aggregation service.